Search

Your search keyword '"Galeano‐Valle, Francisco"' showing total 258 results
Start Over Author "Galeano‐Valle, Francisco"
258 results on '"Galeano‐Valle, Francisco"'

4. COVID-19–associated venous thromboembolism: risk of recurrence and major bleeding

Author

Adarraga, M.D., Alberich-Conesa, A., Amado, C., Amorós, S., Arcelus, J.I., Ballaz, A., Barba, R., Barbagelata, C., Barrón, M., Barrón-Andrés, B., Blanco-Molina, A., Botella, E., Carrero, R., Casado, I., Criado, J., del Toro, J., De Ancos, C., De Juana-Izquierdo, C., Demelo-Rodríguez, P., Díaz-Brasero, A.M., Díaz-Pedroche, M.C., Díaz-Peromingo, J.A., Dubois-Silva, A., Escribano, J.C., Espósito, F., Falgá, C., Farfán-Sedano, A.I., Fernández-Capitán, C., Fernández-Jiménez, B., Fernández-Muixi, J., Fernández-Reyes, J.L., Font, C., Francisco, I., Galeano-Valle, F., García, M.A., García de Herreros, M., García-Bragado, F., García-Ortega, A., Gavín-Sebastián, O., Gil-Díaz, A., Gil-Hernández, A., Gómez-Cuervo, C., Gómez-Mosquera, A.M., González-Martínez, J., Grau, E., Guirado, L., Gutiérrez, J., Hernández-Blasco, L., Jara-Palomares, L., Jaras, M.J., Jiménez, D., Jou, I., Joya, M.D., Lacruz, B., Lalueza, A., Lainez-Justo, S., Lecumberri, R., León-Ramírez, J.M., Lobo, J.L., López-De la Fuente, M., López-Jiménez, L., López-Miguel, P., López-Núñez, J.J., López-Reyes, R., López-Ruiz, A., López-Sáez, J.B., Lorente, M.A., Lorenzo, A., Lumbierres, M., Madridano, O., Maestre, A., Mas-Maresma, L., Marcos, M., Martín-Guerra, J.M., Martín-Martos, F., Mellado, M., Mena, E., Mercado, M.I., Moisés, J., Monreal, M., Muñoz-Blanco, A., Muñoz-Gamito, G., Nieto, J.A., Núñez-Fernández, M.J., Osorio, J., Otalora, S., Pacheco-Gómez, N., Paredes-Ruiz, D., Parra, P., Pedrajas, J.M., Pérez-Ductor, C., Pérez-Jacoiste, A., Pérez-Pérez, J.L., Peris, M.L., Pesce, M.L., Porras, J.A., Poyo-Molina, J., Puchades, R., Riera-Mestre, A., Rivera-Civico, F., Rivera-Gallego, A., Roca, M., Rubio, C.M., Rosa, V., Rodríguez-Cobo, A., Ruiz-Giménez, N., Ruiz-Ruiz, J., Salgueiro, G., Sancho, T., Sendín, V., Sigüenza, P., Soler, S., Suriñach, J.M., Tiberio, G., Tolosa, C., Torres, M.I., Trujillo-Santos, J., Uresandi, F., Usandizaga, E., Valle, R., Varona, J.F., Vela, J.R., Vela, L., Vidal, G., Villalobos, A., Villares, P., Ay, C., Nopp, S., Pabinger, I., Engelen, M., Martens, C., Verhamme, P., Yoo, H.H.B., Arguello, J.D., Montenegro, A.C., Roa, J., Hirmerova, J., Malý, R., Accassat, S., Bertoletti, L., Bura-Riviere, A., Catella, J., Chopard, R., Couturaud, F., Espitia, O., Grange, C., Leclercq, B., Le Mao, R., Mahé, I., Moustafa, F., Plaisance, L., Poenou, G., Sarlon-Bartoli, G., Suchon, P., Versini, E., Schellong, S., Braester, A., Brenner, B., Kenet, G., Najib, D., Tzoran, I., Farrashi, M., Sadeghipour, P., Basaglia, M., Bilora, F., Bortoluzzi, C., Brandolin, B., Ciammaichella, M., Colaizzo, D., Dentali, F., Di Micco, P., Grandone, E., Imbalzano, E., Merla, S., Pesavento, R., Prandoni, P., Scarinzi, P., Siniscalchi, C., Taflaj, B., Tufano, A., Visonà, A., Vo Hong, N., Zalunardo, B., Fonseca, S., Manuel, M., Meireles, J., Bosevski, M., Eftimova, A., Zdraveska, M., Bounameaux, H., Mazzolai, L., Aujayeb, A., Caprini, J.A., Weinberg, I., Bui, H.M., Demelo-Rodriguez, Pablo, Alonso-Beato, Rubén, Jara-Palomares, Luis, Galeano-Valle, Francisco, Bura-Riviere, Alessandra, Visonà, Adriana, Francisco, Iria, Vidal, Gemma, López-Ruiz, Antonio, and Monreal, Manuel

Published
2023
Full Text
View/download PDF

7. Evaluation of soluble P‐selectin as a predictive biomarker in acute symptomatic pulmonary embolism: Insights from a prospective observational study

Author

Oblitas, Crhistian‐Mario, primary, Demelo‐Rodríguez, Pablo, additional, López‐Rubio, Marina, additional, Lago‐Rodríguez, Marta‐Olimpia, additional, García‐Gámiz, Mercedes, additional, Zamora‐Trillo, Angielys, additional, Alvarez‐Sala Walther, Luis‐Antonio, additional, García‐Martínez, Rita, additional, and Galeano‐Valle, Francisco, additional

Published
2024
Full Text
View/download PDF

9. Evaluation of simple laboratory parameters in SARS-CoV-2 infection: the role of ratios

Author

Oblitas, C.M., Galeano Valle, Francisco, Álvarez-Sala Walther, Luis Antonio, Demelo Rodríguez, Pablo, Oblitas, C.M., Galeano Valle, Francisco, Álvarez-Sala Walther, Luis Antonio, and Demelo Rodríguez, Pablo

Abstract

Background: The real predictive prognostic capacity of cellular indices (or ratios) is unclear in SARS-CoV-2 infection. This study aimed to assess the prognostic role of previously well-known laboratory indices and new ones in hospitalized COVID-19 patients. Methods: A retrospective observational study from March to May 2022 evaluated laboratory indices on admission (neutrophil to lymphocyte-, derived neutrophil to lymphocyte-, platelet to lymphocyte-, CRP to lymphocyte-, CRP to albumin-, fibrinogen to lymphocyte-, d-dimer to lymphocyte-, ferritin to lymphocyte-, LDH to lymphocyte-, and IL-6 to lymphocyte ratios), in patients hospitalized due to SARS-CoV2 infection to determine the association with mortality, admission to an intensive care unit (ICU), need for non-invasive mechanical ventilation (NIMV), orotracheal intubation (OTI), or combined event at 30 days follow-up. Results: A total of 1113 COVID-19 patients were evaluated with a mean age of 64.1 ± 15.9 years (58.49% male), 166 (14.91%) patients died, 58 (5.21%) required ICU admission, 73 (6.56%) needed NIMV, 46 (4.23%) needed OTI, and 247 (22.19%) presented the combined event. All the ratios evaluated in this study showed statistical significance in the univariate analysis for mortality and combined event; however, only d-dimer to lymphocyte ratio >0.6 presented an independent association in the multivariate analysis for 30-day mortality (adjusted OR 2.32; p = .047) and 30-day combined event (adjusted OR 2.62; p = .014). Conclusions: Laboratory indices might be a potential biomarker for better prognosis stratification in hospitalized COVID-19 patients. d-Dimer to lymphocyte ratio presents an independent association for 30-day mortality and 30-day adverse outcomes in hospitalized COVID-19 patients., Depto. de Medicina, Fac. de Medicina, TRUE, pub

Published
2024

10. The prognostic value of blood cellular indices in pulmonary embolism.

Author

Siddiqui, Fakiha, Tafur, Alfonso, Hussain, Mushtaq, García‐Ortega, Alberto, Darki, Amir, Fareed, Jawed, Jiménez, David, Bikdeli, Behnood, Galeano‐Valle, Francisco, Fernández‐Reyes, José Luis, Pérez‐Pinar, Montserrat, Monreal, Manuel, Adarraga, MD, Alberich‐Conesa, A, Aibar, J, Alda‐Lozano, A, Alfonso, J, Amado, C, Angelina‐García, M, and Arcelus, JI

Published
2024
Full Text
View/download PDF

18. The Potential Role of CA-125 as a Biomarker for Short-Term Mortality Risk in Patients with Acute Symptomatic Pulmonary Embolism.

Author

Oblitas, Crhistian-Mario, Galeano-Valle, Francisco, Lago-Rodríguez, Marta-Olimpia, López-Rubio, Marina, Baltasar-Corral, Jesús, García-Gámiz, Mercedes, Zamora-Trillo, Angielys, Alvarez-Sala Walther, Luis-Antonio, and Demelo-Rodríguez, Pablo

Subjects
*PULMONARY embolism, *BIOMARKERS, *MORTALITY, *RECEIVER operating characteristic curves, *HEART failure
Abstract

Background: Antigen carbohydrate 125 (CA-125) is a complex glycoprotein extensively studied as a prognostic biomarker in heart failure, yet its potential role in the short-term prognosis of an acute pulmonary embolism (PE) remains unexplored. Methods: In this observational, prospective, single-center study, consecutive patients aged 18 and older with a confirmed acute symptomatic PE and no history of prior anticoagulant therapy were enrolled. Primary and secondary objectives aimed to assess the prognostic capacity of CA-125 at PE diagnosis for 30-day mortality and major bleeding, respectively. Results: A total of 164 patients were included (mean age 69.8 years, SD 17), with 56.1% being male. Within 30 days, 17 patients (10.4%) died and 9 patients (5.5%) suffered major bleeding. ROC curve analysis for 30-day mortality yielded an area under the curve of 0.69 (95% CI 0.53–0.85) with an optimal CA-125 cut-off point of 20 U/mL and a negative predictive value of 96%. Multivariate analysis revealed a significant association between CA-125 levels exceeding 20 U/mL and 30-day mortality (adjusted odds ratio 4.95; 95% CI 1.61–15.2) after adjusting for age, cancer, NT-proBNP > 600 ng/mL, and the simplified pulmonary embolism severity index score. Survival analysis for 30-day mortality exhibited a hazard ratio of 5.47 (95% CI 1.78–16.8). No association between CA-125 levels and 30-day major bleeding was found. Conclusions: CA-125 emerges as a promising surrogate biomarker for short-term mortality prediction in an acute symptomatic PE. Future investigations should explore the integration of CA-125 into PE mortality prediction scores to enhance the prognostic accuracy in this patient population. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Prognostic Significance of Heart Failure in Acute Pulmonary Embolism: A Comprehensive Assessment of 30-Day Outcomes.

Author

Farid-Zahran, Mariam, Méndez-Bailón, Manuel, Pedrajas, José María, Alonso-Beato, Rubén, Galeano-Valle, Francisco, Sendín Martín, Vanesa, Marco-Martínez, Javier, and Demelo-Rodríguez, Pablo

Subjects
HEART failure, PULMONARY embolism, VENTRICULAR ejection fraction, HEART failure patients, PROGNOSIS, MULTIVARIATE analysis
Abstract

Introduction: Patients with heart failure (HF) are known to have an increased risk of pulmonary embolism (PE), but there is limited evidence regarding the prognostic implications of HF in patients with acute PE and the relationship between PE prognosis and left ventricular ejection fraction (LVEF). The primary objective of this study was the development of a composite outcome (mortality, major bleeding, and recurrence) within the first 30 days. The secondary objective was to identify the role of LVEF in predicting the development of early complications in patients with both HF and reduced LVEF. Material and Methods: A prospective study was conducted at two tertiary hospitals between January 2012 and December 2022 to assess differences among patients diagnosed with acute PE based on the presence or absence of a history of HF. Cox regression models were employed to assess the impact of HF and reduced LVEF on the composite outcome at 30 days. Results: Out of 1991 patients with acute symptomatic PE, 7.13% had a history of HF. Patients with HF were older and had more comorbidities. The HF group exhibited higher mortality (11.27% vs. 4.33%, p < 0.001) and a higher incidence of major bleeding (9.86% vs. 4.54%, p = 0.005). In the multivariate analysis, HF was an independent risk factor for the development of the composite outcome (HR 1.93; 95% CI 1.35–2.76). Reduced LVEF was independently associated with a higher risk of major bleeding (HR 3.44; 95% CI 1.34–8.81). Conclusion: In patients with acute pulmonary embolism, heart failure is independently associated with a higher risk of early complications. Additionally, heart failure with reduced LVEF is an independent risk factor for major bleeding. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. COVID-19–associated venous thromboembolism: risk of recurrence and major bleeding

Author

Sanofi España, Laboratorios Farmacéuticos ROVI, Demelo-Rodriguez, Pablo, Alonso-Beato, Rubén, Jara Palomares, Luis, Galeano-Valle, Francisco, Bura-Riviere, Alessandra, Visonà, Adriana, Francisco, Iria, Vidal, Gemma, López-Ruiz, Antonio, Monreal, Manuel, RIETE Investigators, Sanofi España, Laboratorios Farmacéuticos ROVI, Demelo-Rodriguez, Pablo, Alonso-Beato, Rubén, Jara Palomares, Luis, Galeano-Valle, Francisco, Bura-Riviere, Alessandra, Visonà, Adriana, Francisco, Iria, Vidal, Gemma, López-Ruiz, Antonio, Monreal, Manuel, and RIETE Investigators

Abstract

[Background] Complications under anticoagulant treatment in patients with COVID-19-associated venous thromboembolism (VTE) have not been consistently reported., [Objectives] This study aimed to compare the 90-day rates of VTE recurrences and major bleeding in patients with COVID-19-associated VTE versus those with VTE without COVID-19., [Methods] We used the RIETE registry to compare the 3-month outcomes in patients with COVID-19-associated VTE versus those with VTE without COVID-19., [Results] The study included 1,747 patients with COVID-19-associated VTE and 8,711 with VTE without COVID-19. Patients with COVID-19-associated VTE were more likely to be hospitalized at baseline and to present with pulmonary embolism. During the first 90 days, 123 patients (1.17%) developed VTE recurrences, and 266 (2.54%) experienced major bleeding. Patients with COVID-19-associated VTE had a similar rate of VTE recurrences (0.9% vs 1.2%) but a higher rate of major bleeding (4.6% vs 2.1%; P < .001) than those without COVID-19. Multivariable analysis adjusted for competing risks showed that patients with COVID-19-associated VTE had an increased risk of major bleeding (subhazard ratio, 1.395; 95% confidence interval, 1.037-1.877). The 30-day mortality after major bleeding was 26.3% in patients with COVID-19-associated VTE and 17.7% in those without COVID-19., [Conclusion] Patients with COVID-19-associated VTE had a 5-fold higher rate of major bleeding than VTE recurrences during the first 90 days of anticoagulation. In VTE patients without COVID-19, both rates were similar. These findings highlight the importance of carefully monitoring and optimizing anticoagulation in these patients.

Published
2023

28. Evaluation of simple laboratory parameters in SARS-CoV-2 infection: the role of ratios

Author

Oblitas, Crhistian-Mario, primary, Galeano-Valle, Francisco, additional, Cuenca-Carvajal, Carmen, additional, Piqueras-Ruiz, Sandra, additional, Alonso-Beato, Rubén, additional, Alejandre-de-Oña, Álvaro, additional, Carrascosa-Fernández, Paula, additional, Chacón Moreno, Agustín-Diego, additional, Parra-Virto, Alejandro, additional, Pérez Sanz, María-Teresa, additional, Abarca Casas, Laura, additional, Millán-Nohales, Clara, additional, Álvarez-Sala-Walther, Luis, additional, and Demelo-Rodríguez, Pablo, additional

Published
2022
Full Text
View/download PDF

29. Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry

Author

Bikdeli, Behnood, Jiménez, David, Demelo Rodríguez, Pablo, Galeano Valle, Francisco, Porras, José Antonio, Barba, Raquel, Ay, Cihan, Malý, Radovan, Braester, Andrei, Imbalzano, Egidio, Rosa, Vladimir, Lecumberri, Ramón, Siniscalchi, Carmine, Fidalgo, Ángeles, Ortiz, Salvador, Monreal, Manuel, Bikdeli, Behnood, Jiménez, David, Demelo Rodríguez, Pablo, Galeano Valle, Francisco, Porras, José Antonio, Barba, Raquel, Ay, Cihan, Malý, Radovan, Braester, Andrei, Imbalzano, Egidio, Rosa, Vladimir, Lecumberri, Ramón, Siniscalchi, Carmine, Fidalgo, Ángeles, Ortiz, Salvador, and Monreal, Manuel

Abstract

Background: Venous thromboembolism (VTE)—including deep vein thrombosis, pulmonary embolism, and cerebral venous sinus thrombosis (CVST)—may occur early after vaccination against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We sought to describe the site, clinical characteristics, and outcomes of VTE after vaccination against SARS-CoV-2. Methods: In a prospective study using the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) platform, patients with VTE 4–30 days after vaccination against SARS-CoV-2 (1 February 2021 through 30 April 2021) were included. VTE patients recruited from the same centers into RIETE in the same months in 2018–2019 were selected as the reference group. All-cause mortality and major bleeding were the main study outcomes. Results: As of 30 April 2020, 102 patients with post-vaccination VTEs had been identified (28 after adenovirus-based vaccination [ChAdOx1 nCov-19; AstraZeneca] and 74 after mRNA-based vaccination [mRNA-1273; Moderna, and BNT162b2; Pfizer]). Compared with 911 historical controls, patients with VTE after adenovirus-based vaccination more frequently had CVST (10.7% vs. 0.4%, p < 0.001) or thrombosis at multiple sites (17.9% vs. 1.3%, p < 0.001), more frequently had thrombocytopenia (40.7% vs. 14.7%, p < 0.001), and had higher 14-day mortality (14.3% vs. 0.7%; odds ratio [OR]: 25.1; 95% confidence interval [CI]: 6.7–94.9) and major bleeding rates (10.3% vs. 1.0%, OR: 12.03, 95% CI: 3.07–47.13). The site of thrombosis, accompanying thrombocytopenia, and 14-day mortality rates were not significantly different for patients with VTE after mRNA-based vaccination, compared with historical controls. Conclusions: Compared with historical controls, VTE after adenovirus-based vaccination against SARS-CoV-2 is accompanied by thrombocytopenia, occurs in unusual sites, and is associated with worse clinical outcomes., Depto. de Medicina, Fac. de Medicina, TRUE, pub

Published
2022

31. Mid-Regional Pro-Adrenomedullin, Methemoglobin and Carboxyhemoglobin as Prognosis Biomarkers in Critically Ill Patients with COVID-19: An Observational Prospective Study

Author

Oblitas, Crhistian-Mario, primary, Galeano-Valle, Francisco, additional, Ramírez-Navarro, Jesús, additional, López-Cano, Jorge, additional, Monterrubio-Manrique, Ángel, additional, García-Gámiz, Mercedes, additional, Sancho-González, Milagros, additional, Arenal-López, Sara, additional, Álvarez-Sala Walther, Luis-Antonio, additional, and Demelo-Rodríguez, Pablo, additional

Published
2021
Full Text
View/download PDF

32. Predicción de mortalidad y sangrado precoces en pacientes con enfermedad tromboembólica venosa aguda mediante medición de proteína C reactiva

Author

Galeano Valle, Francisco, Demelo Rodríguez, Pablo, Toro Cervera, Jorge del, and Alvarez-Sala Walther, Luis Antonio

Subjects
Sistema cardiovascular
Abstract

Objetivos. La asociación de la medición de la proteína C reactiva (PCR) al diagnóstico y complicaciones precoces en la enfermedad tromboembólica venosa (ETV) aguda no ha sido evaluada. Nuestra hipótesis es que los niveles elevados de PCR al diagnóstico podrían estar asociados con complicaciones precoces (mortalidad, hemorragia, recurrencia) en pacientes con ETV aguda. Material y métodos. Estudio observacional prospectivo, en el que se incluyeron pacientes consecutivos con diagnóstico de ETV aguda en los que se midió la PCR en las primeras 24 horas del diagnóstico. La mortalidad, sangrado y recurrencia fueron registrados durante el seguimiento a 30 días...

Published
2021

33. Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism

Author

Bikdeli, Behnood, primary, Jiménez, David, additional, del Toro, Jorge, additional, Piazza, Gregory, additional, Rivas, Agustina, additional, Fernández‐Reyes, José Luis, additional, Sampériz, Ángel, additional, Otero, Remedios, additional, Suriñach, José María, additional, Siniscalchi, Carmine, additional, Martín‐Guerra, Javier Miguel, additional, Castro, Joaquín, additional, Muriel, Alfonso, additional, Lip, Gregory Y. H., additional, Goldhaber, Samuel Z., additional, Monreal, Manuel, additional, Prandoni, Paolo, additional, Brenner, Benjamin, additional, Farge‐Bancel, Dominique, additional, Barba, Raquel, additional, Di Micco, Pierpaolo, additional, Bertoletti, Laurent, additional, Schellong, Sebastian, additional, Tzoran, Inna, additional, Reis, Abilio, additional, Bosevski, Marijan, additional, Bounameaux, Henri, additional, Malý, Radovan, additional, Verhamme, Peter, additional, Caprini, Joseph A., additional, Bui, Hanh My, additional, Adarraga, María Dolores, additional, Agud, María, additional, Aibar, Jesús, additional, Aibar, Miguel Ángel, additional, Amado, Cristina, additional, Arcelus, Juan Ignacio, additional, Baeza, Carlos, additional, Ballaz, Aitor, additional, Barbagelata, Cristina, additional, Barrón, Manuel, additional, Barrón‐Andrés, Belén, additional, Blanco‐Molina, Ángeles, additional, Botella, Ernesto, additional, Camon, Ana María, additional, Cañas, Inmaculada, additional, Casado, Ignacio, additional, Chasco, Leyre, additional, Criado, Juan, additional, de Ancos, Cristina, additional, de Miguel, Javier, additional, Demelo‐Rodríguez, Pablo, additional, Díaz‐Peromingo, José Antonio, additional, Di Campli, Mario Virgilio, additional, Díez‐Sierra, Javier, additional, Domínguez, Irene Milagros, additional, Escribano, José Carlos, additional, Falgá, Conxita, additional, Farfán‐Sedano, Ana Isabel, additional, Fernández‐Capitán, Carmen, additional, Fernández‐Reyes, Jose Luis, additional, Fidalgo, María Ángeles, additional, Flores, Katia, additional, Font, Carme, additional, Font, Llorenç, additional, Francisco, Iria, additional, Gabara, Cristina, additional, Galeano‐Valle, Francisco, additional, Galindo, David, additional, García, María Angelina, additional, García‐Bragado, Ferrán, additional, García de Herreros, Marta, additional, García‐Hernáez, Raquel, additional, García‐Mullor, María Mar, additional, García‐Raso, Arantxa, additional, Gavín‐Sebastián, Olga, additional, Gil‐Díaz, Aida, additional, Gómez‐Cuervo, Covadonga, additional, Grau, Enric, additional, Guirado, Leticia, additional, Gutiérrez, Javier, additional, Hernández‐Blasco, Luis, additional, Hernando, Elena, additional, Herreros, Miguel, additional, Jara‐Palomares, Luis, additional, Jaras, María Jesús, additional, Jiménez, Rafael, additional, Joya, Maria Dolores, additional, León, José Manuel, additional, Lima, Jorge, additional, Llamas, Pilar, additional, Lobo, José Luis, additional, López‐Jiménez, Luciano, additional, López‐Miguel, Patricia, additional, López‐Núñez, Juan José, additional, López‐Reyes, Raquel, additional, López‐Ruiz, Antonio, additional, López‐Sáez, Juan Bosco, additional, Lorenzo, Alicia, additional, Madridano, Olga, additional, Maestre, Ana, additional, Marchena, Pablo Javier, additional, Martín del Pozo, Mar, additional, Martín‐Martos, Francisco, additional, Mella, Carmen, additional, Mellado, Meritxell, additional, Mercado, Maria Isabel, additional, Moisés, Jorge, additional, del Valle Morales, María, additional, Muñoz‐Blanco, Arturo, additional, Muñoz‐Rivas, Nuria, additional, Navas, María Sierra, additional, Nieto, Jose Antonio, additional, Núñez‐Fernández, Manuel Jesús, additional, Obispo, Berta, additional, Olid, Mónica, additional, Olivares, María Carmen, additional, Orcastegui, José Luis, additional, Ortega‐Michel, Clara, additional, Osorio, Jeisson, additional, Otalora, Sonia, additional, Parra, Pedro, additional, Parra, Virginia, additional, Pedrajas, José María, additional, Pellejero, Galadriel, additional, Porras, José Antonio, additional, Portillo, José, additional, Riera‐Mestre, Antoni, additional, Rivera‐Civico, Francisco, additional, Rodríguez‐Chiaradía, Diego Agustín, additional, Rodríguez‐Cobo, Ana, additional, Rodríguez‐Matute, Consolación, additional, Rogado, Jacobo, additional, Roig, Sonia, additional, Rosa, Vladimir, additional, Ruiz‐Artacho, Pedro, additional, Ruiz‐Giménez, Nuria, additional, Ruiz‐Ruiz, Justo, additional, Ruiz‐Sada, Pablo, additional, Salgueiro, Giorgina, additional, Sánchez‐Martínez, Rosario, additional, Sánchez‐Muñoz‐Torrero, Juan Francisco, additional, Sancho, Teresa, additional, Sirisi, Merçe, additional, Soler, Silvia, additional, Tirado, Raimundo, additional, Torres, María Isabel, additional, Tolosa, Carles, additional, Trujillo‐Santos, Javier, additional, Uresandi, Fernando, additional, Valero, Beatriz, additional, Valle, Reina, additional, Vela, Jerónimo Ramón, additional, Vidal, Gemma, additional, Villares, Paula, additional, Zamora, Carles, additional, Gutiérrez, Paula, additional, Vázquez, Fernando Javier, additional, Engelen, Matthias, additional, Vanassche, Thomas, additional, Hirmerova, Jana, additional, Salgado, Estuardo, additional, Ait Abdallah, Nassim, additional, Bura‐Riviere, Alessandra, additional, Crichi, Benjamin, additional, Debourdeau, Philippe, additional, Olivier, Espitia, additional, Falvo, Nicolas, additional, Galliazzo, Silvia, additional, Helfer, Hélène, additional, Mahé, Isabelle, additional, Moustafa, Farès, additional, Poenou, Geraldine, additional, Braester, Andrei, additional, Bilora, Franca, additional, Bucherini, Eugenio, additional, Ciammaichella, Maurizio, additional, Imbalzano, Egidio, additional, Maida, Rosa, additional, Mastroiacovo, Daniela, additional, Pace, Federica, additional, Pesavento, Raffaele, additional, Pomero, Fulvio, additional, Quintavalla, Roberto, additional, Rocci, Anna, additional, Romualdi, Roberta, additional, Tufano, Antonella, additional, Visonà, Adriana, additional, Zalunardo, Beniamino, additional, Gibietis, Valdis, additional, Kigitovica, Dana, additional, Skride, Andris, additional, Fonseca, Samuel, additional, Martins, Filipa, additional, Meireles, Jose, additional, Mazzolai, Lucia, additional, Bikdeli, Behnood, additional, Tafur, Alfonso J., additional, Ochoa‐Chaar, Cassius Iyad, additional, Weinberg, Ido, additional, and Wilkins, Hannah, additional

Published
2021
Full Text
View/download PDF

35. Inflammatory Biomarkers in the Short-Term Prognosis of Venous Thromboembolism: A Narrative Review

Author

Galeano Valle, Francisco, Ordieres Ortega, Lucía, Oblitas, Crhistian Mario, Toro Cervera, Jorge del, Álvarez-Sala Walther, Luis Antonio, Demelo Rodríguez, Pablo, Galeano Valle, Francisco, Ordieres Ortega, Lucía, Oblitas, Crhistian Mario, Toro Cervera, Jorge del, Álvarez-Sala Walther, Luis Antonio, and Demelo Rodríguez, Pablo

Abstract

The relationship between inflammation and venous thrombosis is not well understood. An inflammatory response may be both the cause and consequence of venous thromboembolism (VTE). In fact, several risk factors of VTE modulate thrombosis through inflammatory markers. Acute pulmonary embolism (PE) is burdened by a remarkable mortality rate, up to 34% in severely ill patients presenting with hemodynamic instability. Initial mortality risk stratification is based on hemodynamic instability. Patients with a situation of hemodynamic stability require immediate further risk assessment based on clinical, imaging, and circulating biomarkers, as well as the presence of comorbidities. Some inflammatory biomarkers have shown potential usefulness in the risk stratification of patients with VTE, especially acute PE. C-reactive protein on admission is associated with 30-day mortality and bleeding in VTE patients. P-selectin is associated with right ventricle dysfunction in PE patients and might be associated with VTE recurrences and the extension of thrombosis. Tissue factor microparticles are associated with VTE recurrence in cancer-associated thrombosis. Other inflammatory biomarkers present scarce evidence (inflammatory cytokines, erythrocyte sedimentation rate, fibrinogen, leukocyte count). In this manuscript, we will review the prognostic role of different inflammatory biomarkers available both for clinical practice and research in VTE patients., Depto. de Medicina, Fac. de Medicina, TRUE, pub

Published
2021

36. Mid-Regional Pro-Adrenomedullin, Methemoglobin and Carboxyhemoglobin as Prognosis Biomarkers in Critically Ill Patients with COVID-19: An Observational Prospective Study

Author

Oblitas, Crhistian Mario, Galeano Valle, Francisco, Ramírez Navarro, Jesús, López Cano, Jorge, Monterrubio Manrique, Ángel, García Gámiz, Mercedes, Sancho González, Milagros, Arenal López, Sara, Álvarez Sala Walther, Luis Antonio, Demelo Rodríguez, Pablo, Oblitas, Crhistian Mario, Galeano Valle, Francisco, Ramírez Navarro, Jesús, López Cano, Jorge, Monterrubio Manrique, Ángel, García Gámiz, Mercedes, Sancho González, Milagros, Arenal López, Sara, Álvarez Sala Walther, Luis Antonio, and Demelo Rodríguez, Pablo

Abstract

Depto. de Medicina, Fac. de Medicina, TRUE, pub

Published
2021

37. Predicción de mortalidad y sangrado precoces en pacientes con enfermedad tromboembólica venosa aguda mediante medición de proteína C reactiva

Author

Demelo Rodríguez, Pablo, Toro Cervera, Jorge del, Alvarez-Sala Walther, Luis Antonio, Galeano Valle, Francisco, Demelo Rodríguez, Pablo, Toro Cervera, Jorge del, Alvarez-Sala Walther, Luis Antonio, and Galeano Valle, Francisco

Abstract

Objetivos. La asociación de la medición de la proteína C reactiva (PCR) al diagnóstico y complicaciones precoces en la enfermedad tromboembólica venosa (ETV) aguda no ha sido evaluada. Nuestra hipótesis es que los niveles elevados de PCR al diagnóstico podrían estar asociados con complicaciones precoces (mortalidad, hemorragia, recurrencia) en pacientes con ETV aguda. Material y métodos. Estudio observacional prospectivo, en el que se incluyeron pacientes consecutivos con diagnóstico de ETV aguda en los que se midió la PCR en las primeras 24 horas del diagnóstico. La mortalidad, sangrado y recurrencia fueron registrados durante el seguimiento a 30 días..., Aims. The association of on-admission C-reactive protein (CRP) and early adverse outcomes in acute venous thromboembolism (VTE) has not been investigated. We hypothesized that increased on-admission CRP levels is associated with early adverse outcomes (mortality, bleeding, recurrence) in patients with acute VTE. Method. In this prospective observational study, consecutive patients with acute VTE were enrolled and CRP levels were measured within the first 24 hours after diagnosis. Mortality, bleeding and recurrence were recorded during a 30-day follow-up...

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results